IMPL.Q Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
IPI Legacy Liquidation Co Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
IMPL.Q Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
IPI Legacy Liquidation Co Key Details
Last Reported Earnings
Sep 30, 2023
Next Reporting Earnings
n/a
- -3.11
- 52.58%
- -353.93%
- -120.8%
About IMPL.Q
- Founded
- 2008
- Employees
- 160
- CEO
- WebsiteView website
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
